Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 3Recruiting 2Suspended 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 37Melanoma 17Prostatic Neoplasms 16Lung Neoplasms 14Neoplasms 13Squamous Cell Carcinoma of Head and Neck 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 9Precancerous Conditions 8Lymphoma 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Leukemia 6Esophageal Neoplasms 6Colorectal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms, Male 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Follicular 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Barrett Esophagus 5Adenocarcinoma Of Esophagus 5Salivary Gland Neoplasms 4Recurrence 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4

Interventions

Ifosfamide 17Methotrexate 16Doxorubicin 14Filgrastim 13Etoposide 12Cisplatin 12Cyclophosphamide 10Gemcitabine 9Leucovorin 8Sirolimus 6Carboplatin 6Topotecan 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Temozolomide 4Sorafenib 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Docetaxel 4trimetrexate glucuronate 3temsirolimus 3dinutuximab 3cixutumumab 3apatinib 3Vincristine 3Specimen Handling 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Osteosarcoma × Biopsy × Clear all
NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 12 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡